Beyond Solvents: The Future Of Sustainable Amorphous Dispersion Development

By Elizabeth Hickman, CEO

Sustainability in pharmaceutical manufacturing is often framed as an environmental goal, yet its greatest impact emerges through efficiency, predictability, and asset value. Traditional solvent‑based amorphous dispersion processes introduce hidden complexity by requiring large solvent volumes, extensive recovery systems, and energy‑intensive operations. These inefficiencies increase cost, extend development timelines, and heighten supply‑chain vulnerability as programs move toward commercialization.

A more streamlined manufacturing approach shifts sustainability from a compliance objective to a performance driver. Eliminating unnecessary steps and infrastructure reduces material waste, operational burden, and variability while improving control and scalability. Manufacturing systems designed around fewer dependencies allow scale to be achieved through throughput adjustments rather than redevelopment, creating smoother transitions from development to commercial production. The resulting model supports shorter timelines, lower risk, and greater resilience, enabling teams to reinvest time and capital into advancing the product itself. In this context, sustainability becomes a foundational element of long‑term pharmaceutical value rather than a secondary consideration.